RCS - Eco Animal Health Gp - Head of Global R&D

ECO Animal Health

01/10/2025 07:00

RNS Number : 5057B

Eco Animal Health Group PLC

01 October 2025

 

1 October 2025

 

 

ECO Animal Health Group plc
 (''ECO" or the "Company")

 

Head of Global R&D

 

ECO Animal Health (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, confirms that Hafid Benchaoui, Head of Global R&D, will be leaving ECO Animal Health to pursue a new opportunity in the companion animal health industry.

 

The Company is making good progress towards recruiting a new Head of Global R&D, and Hafid will remain in place until 21 October to ensure an orderly handover of his responsibilities. ECO Animal Health continues to benefit from a highly experienced senior R&D team, and all developments within the Company's R&D pipeline remain on track.

 

The Board would like to take this opportunity to thank Hafid for his contribution to ECO Animal Health and wish him the best in his future endeavours.

 

The Company will provide further updates in due course.

 

-Ends-

 

Contacts

ECO Animal Health Group plc
David Hallas (Chief Executive Officer)
Christopher Wilks (Chief Financial Officer)
020 8447 8899
ICR Healthcare (Financial PR)
Mary-Jane Elliott
Jessica Hodgson
020 3709 5700
Singer Capital Markets (Nominated Adviser & Joint Broker)
Philip Davies
Sam Butcher
020 7496 3000
Panmure Liberum (Joint Broker)
Emma Earl
Will Goode
Mark Rogers
Rupert Dearden
020 3100 2000
Equity Development
Hannah Crowe
Matt Evans
020 7065 2692

 

 

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

 

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

 

Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.

 

Click here for more information: https://ecoanimalhealth.com

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
NRAWPUQWBUPAGRU